How and why tumors metastasize is still a matter of debate. The assumption is that mutations render tumor cells with a metastatic phenotype, enabling entrance in and transport through lymph or blood vessels. Distant outgrowth is thought to occur only in a suitable microenvironment (the seed and soil hypothesis). However, the anatomical location of most metastases in cancer patients suggests entrapment of tumor cells in the first microcapillary bed that is encountered. We here investigated how vascular endothelial growth factor-A (VEGF-A) attributes to the metastatic process. We describe here that VEGF-A enhances spontaneous metastasis by inducing intravasation of heterogeneous tumor cell clusters, surrounded by vessel wall elements, via an invasionindependent mechanism. These tumor clusters generate metastatic tissue embolisms in pulmonary arteries. Treatment of tumor-bearing mice with the antiangiogenic compound ZD6474 prevented the development of this metastatic phenotype. This work shows that tumors with high constitutive VEGF-A expression metastasize via the formation of tumor emboli and provides an alternative rationale for anti-VEGF-A therapy, namely to inhibit metastasis formation.
Introduction
Most cancer patients die from complications that result from metastases, rather than from a primary tumor. Lung metastasis is a most feared complication of a significant proportion of cancers, for example mamma carcinoma, renal cell carcinoma and head and neck tumors. The exact mechanisms of metastasis are still matter of debate. The current hypothesis is that tumor cells accumulate mutations that result in a metastatic phenotype, characterized by the capacity to invade blood and lymph vessels (Ellis and Fidler, 1996) . After transport, cells adhere to endothelium, extravasate or grow intravascularly (Al-Mehdi et al., 2000) and then grow to clinically relevant lesions at distant sites, provided that these sites constitute a suitable niche (the seed and soil hypothesis, Fidler (2003) ). It was recently described that such niches can also be prepared by bone marrow-derived cells to allow metastatic growth (Kaplan et al., 2005) .
Although it is well known that expression of vascular endothelial growth factor-A (VEGF-A) and the concomitant increase in vessel density correlates with poor prognosis in a number of tumor types (Weidner and Folkman, 1996; Weidner, 1998; Hasan et al., 2002) , the mechanism behind this correlation is also not exactly understood, although several explanations may be applicable: tumor cells that secrete VEGF-A may be more successful in outgrowing its dormant state after metastatic deposition (Folkman, 1990; Ellis and Fidler, 1996) . Also, the probability of tumor cell entry into the blood is expected to increase with vessel density.
Yet, there are arguments against both explanations. First, clinical and animal data show that for metastatic tumors in brains, lungs or livers, induction of angiogenesis is not a prerequisite as for these tumors the preexistent vascular bed may allow tumor growth (Pezzella et al., 1997; Al-Mehdi et al., 2000; Neves et al., 2001; Vermeulen et al., 2001; Kim et al., 2002; Kusters et al., 2002; Passalidou et al., 2002; Auguste et al., 2005) . Secondly, recent reports demonstrated the presence of intravascular endothelium-covered tumor cell clusters in the primary tumor as origin of metastasis (Sugino et al., 1993 (Sugino et al., , 2002 (Sugino et al., , 2004 . Clinical and preclinical data suggest that not the amount of circulating single tumor cells but rather that of circulating tumor cell clusters correlate with development of metastases (Fidler, 1973; Liotta et al., 1976; Glaves, 1983; Vlems et al., 2003) . At this moment it is not clear whether these clusters have a single cell origin or are derived from tumor cell aggregates that dissociated from the primary tumor and intravasated as such. Support for the latter hypothesis comes from studies showing that spontaneous metastases derived from genetically polyclonal tumors were, at least in part, also polyclonal (Moffett et al., 1992) .
Most investigations in the field of metastasis have been performed using colonization approaches in which tumor cells are hematogenously directed to the organs of interest (Fidler, 1996; Killion et al., 1998) . These colonization models lack the initial event of tumor cell entry into the blood stream, an important and possibly rate-limiting step. Here we investigated which steps of the metastatic process are influenced by VEGF-A.
Results

VEGF-A does not increase metastatic burden in colonization assays
To investigate whether VEGF-A enhanced brain colonization by Mel57, a human melanoma cell line with low to undetectable levels of endogenous VEGF-A (Kusters et al., 2003) , we injected a 1:1 mixture of Mel57-VEGF-A cells and Mel57-enhanced green fluorescent protein (EGFP) cells (serving as VEGF-A-negative control cells) into the internal carotid artery of nude mice and analysed numbers and composition of brain lesions by anti-EGFP immunostaining and in situ hybridization (ISH) for VEGF-A. More than 85% of the lesions grew by clonal expansion as they consisted of either Mel57-EGFP cells or Mel57-VEGF-A cells (Figure 1a , upper two panels and Figure 1b ). There was no significant difference between numbers of EGFP-and VEGF-Aexpressing lesions (Figure 1b ), ruling out a stimulatory effect of VEGF-A in this colonization model. These data were confirmed in a second colonization assay, in which a mixture of Mel57-VEGF-A and Mel57-EGFP cells was injected into the tail vein. Again, tumors developed in brain predominantly by clonal expansion of single tumor cells (Figure 1c) . Remarkably, although multiple lesions developed in the brains of these animals, no or only few lung lesions were detected, indicating a strong preference of the melanoma cells for brain parenchyma.
Morphology of subcutaneous tumors: VEGF-A-induced micronodular transformation
Mel57-EGFP and Mel57-VEGF-A subcutaneous tumors were characterized on the morphological and immunohistochemical level. Parental Mel57 and Mel57-EGFP tumors behaved similarly with respect to growth rate (not shown) and had comparable phenotypes. They developed relatively slowly and were highly necrotic (Figure 2a) , leaving a small rim of viable tumor tissue that was sparsely vascularized (Figure 2d) . A completely different growth rate and architecture was observed with Mel57-VEGF-A xenografts. These grew rapidly to large, histologically viable-appearing tumors with a distinct morphology (Figure 2b and c, e-i). Tumors were composed of multiple micronodules that were surrounded by a network of laminin, endothelial cells and pericytes (Figure 2e -i, see also Figure 4g ). Some of these (smaller) nodules were protruding in large sinusoidal vessels (Figure 2c , e, g and respective insets).
A double staining for a-smooth muscle actin (a-SMA) and CD34 revealed a composition in which the pericytes were located on the inside, whereas endothelial cells were at the outer edge (Figure 2i ). This is consistent with a model of bulging of micronodules into dilated vessels during which process nodules become gradually covered by vessel wall elements as previously suggested (Sugino et al., 2002) . Sometimes, small nodules in the tumor periphery appeared only loosely, if at all, attached to the vessel wall and impressed as tumor emboli. Instead of widespread central necrosis, as observed in parental Mel57 xenografts, the larger individual tumor nodules in the tumor center showed small areas of central necrosis (compare Figure 2b and a) . Mice were killed when EGFP and VEGF-A tumors had reached similar sizes ( Figure 3a ) and metastatic burden and composition of the lesions were analysed by anti-EGFP immunostaining and VEGF-A mRNA ISH. VEGF-A expression significantly increased the probability of lung metastasis formation. More than 90% of lung lesions were derived from the Mel57-VEGF-A xenografts (P ¼ 0.043, Figure 3b ). Tumors were always localized within the larger branches of pulmonary arteries ( Figure 3c , arrows), strongly suggesting that these originated from tumor embolisms. Interestingly, despite the strong preference of the Mel57 cells for brain, which was apparent from the intravenous colonization assays, brain metastases were never detected in mice carrying subcutaneous Mel57 xenografts.
VEGF-A-induced micronodular growth facilitates the formation of multicellular tumor emboli
To examine in more detail the composition of the tumor emboli in the lungs, we injected a 1:1 mixture of Mel57-EGFP and Mel57-VEGF-A cells into the flank of nude mice to establish mixed subcutaneous tumors. The resulting xenografts showed comparable growth profiles and phenotypes as Mel57-VEGF-A xenografts (see hematoxylin and eosin (H&E) staining in the inset in Figure 4a ). The composition of most lung deposits was polyclonal with both Mel57-EGFP and Mel57-VEGF-A cells, very similar to the micronodules in the primary tumors (EGFP stainings in Figure 4a , b and VEGF-A ISH in Figure 4h ). VEGF-A ISH and EGFP stainings were complementary (not shown), indicating that transgenic proteins were stably expressed and that no confounding loss of expression had occurred. Only a small fraction of the lesions was clonal, containing either Mel57-EGFP or Mel57-VEGF-A cells (Figure 4l ). This reflected the composition of the primary tumors where occasionally nodules were found that consisted of a single-cell type, probably also arising by clonal expansion within the primary tumor (Figure 4c , arrowheads). Interestingly, in the right ventricle of one tumor-bearing animal, we found micronodules of the same mosaic composition as the primary tumor and the lung lesions (Figure 4d and inset). Again, these nodules had tissue characteristics as they contained laminin (Figure 4e 
ZD6474 prevents formation of the metastatic phenotype
We treated Mel57-VEGF-A xenografts with 50 mg/kg ZD6474, a tyrosine kinase inhibitor which targets VEGFR2 and the epidermal growth factor receptor (EGFR) (Wedge et al., 2002) , starting at day 8 post tumor cell inoculation, when small tumors were already visible. Further outgrowth of xenografts was effectively inhibited as compared to tumors in placebo-treated animals ( Figure 5a ). (Immuno)histological analysis after 27 days of therapy revealed small tumors with large necrotic areas. Interestingly, treated tumors still presented with a nodular phenotype, but the nodules lacked These results suggest that metastatic emboli escape the tumor during early stages of tumor growth. Furthermore, they show that ZD6474 treatment does not inhibit metastatic outgrowth in lungs, possibly reflecting the potential to grow by cooption in highly vascularized tissues (Passalidou et al., 2002; Leenders et al., 2004) . Furthermore, the intravascular localization of these metastases, very near to air-filled alveoli, may enable tumor growth without additional angiogenesis.
Discussion
Tumor dissemination is a complex multistep process, requiring migration through matrix, intravasation, transport, extravasation and outgrowth. Interactions between tumor and stromal cells at distant sites are eminently important and metastatic niches may be prepared by bone marrow-derived cells (Kaplan et al., 2005) . Tumor dissemination to liver and lungs may differ from that to other parts in the body, because the microcapillary beds in these organs act as passive filters, trapping tumor cells or tumor fragments. Thus, metastasis may also be looked at as a passive event in which tumor cells or clusters are trapped in pulmonary arterioles or capillaries and grow intravascularly before breaking through the vessel wall and spreading further (Al-Mehdi et al., 2000) . Expression of VEGF-A by tumors and concomitant high tumor vessel densities have been associated with poor prognosis in a number of cancer types (Ferrara, 2002; Hasan et al., 2002) , supposedly owing to an increased chance of tumor cell intravasation. However, correlations between high vessel densities and numbers of circulating tumor cells have never been established although the presence of circulating tumor cell clusters does correlate with prognosis (Liotta et al., 1976; Vlems et al., 2003) .
In our brain colonization models of mixed Mel57-VEGF-A/Mel57-EGFP cell populations, metastases developed predominantly by clonal outgrowth of single cells, which is in agreement with observations by others (Fidler and Talmadge, 1986) . Interestingly, upon injection of Mel57 cells into the tail vein, multiple brain lesions but only few lung lesions developed, indicating a clear preference of this cell line to colonize brain (compatible with the 'seed and soil' hypothesis (Fidler, 2003) ). In these assays, VEGF-A did not increase tumor burden in brains, consistent with previous reports (Yano et al., 2000) . In contrast, Mel57-VEGF-A subcutaneous tumors metastasized to lungs much more efficiently than Mel57-EGFP tumors. In fact, the VEGF-A effects may have been underestimated because Mel57-VEGF-A tumors had 5 weeks less time to metastasize than the Mel57-EGFP xenografts. Altogether, these data suggest that VEGF-A exerts its effect on the level of tumor cell intravasation.
Our results show convincingly that VEGF-A-expressing tumor cells detached from the primary tumor as VEGF-A-induced tumor emboli as origin of metastasis B Küsters et al tissue fragments, covered by vessel wall elements. These fragments entered the circulation, were captured in the lung capillary bed and grew out, initially intravascularly. This model is consistent with the presence of micronodules in the circulation such as in a right heart ventricle and in peritumoral-dilated vasculature in the xenografts. Such nodules were observed only occasionally, which is expected as these are carried away by the circulation instantly, similar to the model proposed by Sugino et al. (2002) .
Thus, VEGF-A induces a passive metastatic phenotype that results in dissemination to lung. How does this phenotype evolve? It appears from our data that endothelial cells and pericytes in dilated vasculature are induced by tumor-derived VEGF-A to proliferate and migrate, thus covering up the micronodules that gradually protrude into the lumen of these vessels. This scheme of events would indeed predict the observed topology of endothelial cells and pericytes on nodules. Tumor nodules that are located suboptimally for intravasation will remain localized and grow out to make up the main tumor mass.
Our data provide an explanation for the lack of correlation between circulating tumor cells and prognosis (Vlems et al., 2003) : PCR-based techniques on blood samples do not distinguish between tumor cell clusters with metastatic capacity and single circulating tumor cells that may not be able to survive because they are not in a 'tumor-tissue' context. It is also tempting to speculate that coverage by endothelial cells leads to protection from the immune system, thus further increasing the chance of successful metastatic deposition.
Our study places an important footnote to the prevailing view that metastases arise by clonal outgrowth of single tumor cells that have acquired a metastatic phenotype (Fidler and Talmadge, 1986; Fidler, 1996; Fidler et al., 1999) . In fact, tumor cells like Mel57-EGFP that metastasize inefficiently, can successfully travel along with VEGF-A-expressing tumor cells. This may explain the occasional presence in cancer patients of metastases that have little angiogenic potential although they originated from highly angiogenic primary tumors (Pezzella, 2000) . Tumor tissue fragments may have high clinical relevance as these are frequently found in lymph and blood vessels of cancer patients with poor prognosis Weidner, 2002) . Interestingly, renal clear cell carcinomas, which frequently show constitutive VEGF-A expression, also frequently display a nodular phenotype and intravascular growth (Sugino et al., 2004) .
Clearly, VEGF-A does not always induce metastatic dissemination (Kanayama et al., 1999; Gannon et al., 2002) . The effect of VEGF-A that we describe here may be tumor specific to a certain extent. In a mouse model of metastatic mammary carcinoma, metastatic potential was attributed to pleiotrophin (Sugino et al., 1993 (Sugino et al., , 2002 ). An exclusive role for this protein in our tumors can be excluded as this factor is also expressed in parental Mel57 cells . E-cadherin has been described to be essential for intercellular tumor cell adhesion in circulating tumor cell clusters (Tomlinson et al., 2001; Alpaugh et al., 2002) . In our model, however, neither the parental nor the VEGF-A tumors expressed E-cadherin (unpublished results).
Anti-VEGF therapy is considered to be a valuable approach to prevent clinical manifestations of metastatic disease in cancer patients. By inhibiting angiogenesis, minute metastatic deposits should remain dormant, turning cancer into a chronic disease. However, the angiogenesis dependency of tumors in vessel-dense organs may be not strict because tumors may incorporate pre-existent vasculature (Leenders et al., , 2004 . Our results point to a possible novel role for antiangiogenic therapy: anti-VEGF therapy in patients with primary cancers might decrease the chance of metastatic spread, not simply by decreasing vascular density, but rather by preventing the formation of metastatic tissue. Whether such application will have future relevance remains to be seen, as patients with primary tumors are generally no candidates for anti-VEGF therapies.
Materials and methods
Animals
Specific pathogen-free male (SPF), 6-8-week-dd old BALB/c nu/nu mice were housed under SPF conditions (five mice/cage, temperature 20-241C; relative humidity 50-60%; 15 air VEGF-A-induced tumor emboli as origin of metastasis B Küsters et al changes per hour; light-dark periods 14 h/10 h). Water and food were available to the animals ad libitum. Experiments were carried out in accordance with the national animal protection laws.
ZD6474 treatment
A suspension of ZD6474 in 0.5% Tween-80 was given daily by oral gavage at a dose of 50 mg/kg. Treatment was initiated 8 days post-injection of tumor cells, when tumors had grown to approximately 100 mm 3 or after 4 weeks. Tumors were measured twice weekly with calipers, and tumor volumes were expressed as height Â depth Â width. Mice were killed at day 45, and analysed for tumor composition and lung metastasis.
Cell lines and transfections
Stable transfectants of Mel57-expressing EGFP and VEGF-A165 were described elsewhere . VEGF-A expression levels in conditioned media were determined by enzyme-linked immunosorbent assay as described previously (Span et al., 2000) and were 30-50ng/10 6 cells/24 h in the VEGF-A transfectants and o10 pg VEGF/10 6 cells/24 h in the EGFP transfectants. There was no difference between growth rates of the different cell lines in vitro (not shown).
Colonization and metastasis models Colonization models Equal numbers (5 Â 10 4 ) of Mel57-VEGF-A and Mel57-EGFP cells were coinjected into the internal carotid artery for induction of brain metastases as described (n ¼ 11) (Kusters et al., 2001 . Similarly, 6 Â 10 6 Mel57-VEGF and Mel57-EGFP cells (in a 1:1 ratio) were injected into the tail vein of nude mice (n ¼ 7) to examine homing to lung and brain. Animals were killed after 2-3 weeks when mice developed cachexia or acute neurological defects.
Spontaneous metastasis Subcutaneous tumors were induced in nude mice by injection of a mixture of Mel57-VEGF-A and Mel57-EGFP cells into the flank (1 Â 10 6 cells for each cell line, n ¼ 9). In a second experiment, a Mel57-EGFP tumor was grown on the right flank and a Mel57-VEGF-A tumor on the left flank (2 Â 10 6 cells per flank) (n ¼ 5). Mel57-EGFP cells were injected 5 weeks before Mel57-VEGF-A cells to ensure that both tumors were of comparable size at the time of analysis.
Mice were killed after development of severe cachexia owing to tumor load. In two out of five animals carrying tumors on both flanks, Mel57-EGFP tumors had to be removed because of severe ulceration after 6 weeks of tumor growth. These mice were still included in the analysis of metastatic composition.
Histological and immunohistochemical analysis
For (immuno)histochemistry, 4 mm sections of formalin-fixed and paraffin-embedded tissues (subcutaneous tumor, heart, lung and/or brain) were treated as described before Kusters et al., 2002) . Antibodies were anti-EGFP (a kind gift of Dr E Cuppen, Department of Cell Biology, University Nijmegen Medical Center, The Netherlands), antimouse CD34 (Hycult Biotechnology, Uden, The Netherlands), rabbit anti-mouse Ki-67 (Dianova, Hamburg, Germany), mouse anti-a-SMA (a-Sm1, Sigma, Zwijndrecht, The Netherlands) and rabbit anti-laminin (Dako, Glostrup, Denmark). To detect Mel57-VEGF-A cells, we performed ISH on 10 mm sections using a digoxigenin-labeled VEGF-A antisense RNA as probe and the corresponding sense RNA as a control, using standard techniques. Double stainings for CD34 and a-Sm1 were performed on 4 mm sections of paraffin-embedded tumors as follows. After deparaffinization and rehydration, endogenous peroxidase was blocked by a 30-min incubation in 3% hydrogen peroxide in phosphate-buffered saline (PBS). After rinsing in PBS (three times for 5 min each), the sections were boiled in citrate buffer (10 mM, pH 6.0) for antigen retrieval. After blocking, sections were incubated overnight at 41C with the rat monoclonal CD 34 primary antibody that was subsequently visualized by subsequent incubations with a biotinylated secondary anti-rat antibody and alkaline phosphatase (AP)-conjugated avidin. AP was developed with Fast Blue.
After that sections were blocked again and incubated overnight at 41C with the a-SMA antibodies. These were visualized by horseradish peroxidase (HRP)-labeled secondary antibodies and AEC reagent, resulting in a red staining.
Statistical analysis
In each mouse, the number of microscopic lesions consisting of EGFP-or VEGF-A-expressing cells and mixed lesions were counted. From these numbers, ratios of monoclonal/polyclonal lesions were calculated. For subcutaneous tumors, volumes were determined by multiplying height Â width Â depth. The softwareprogram SPSS (SPSS 9.0 for Windows, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Differences were considered significant when Po0.05, as determined by Wilcoxon-signed rank test. Analyses were performed both on absolute numbers and ratios, where appropriate.
